EUVIMEDEUVIMED entdecken
Crossref

Jieduquyuziyin prescription ameliorates systemic lupus erythematosus by targeting MAPK14 to inhibit SAA3-induced macrophage M1 polarization

Xinhui Lu, Yan Huang, Manchao Liu, Li Xu, Xi Chen, Yinghui Wei, Yihan Zhou, Hang Jin, Fengyu Lu, Yujun Tang, Chengping Wen

Phytomedicine · 2026-10 · 160 · 158659

DOI: 10.1016/j.phymed.2026.158659 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2026-10. Verfasst von Xinhui Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Chinese Medicine Rheumatology of Zhejiang Province, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou…. Hauptthemen laut MEDLINE: Serum Amyloid A Protein, Lupus Erythematosus, Systemic, Macrophages, Drugs, Chinese Herbal. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease involving inflammatory macrophage polarization and hepatic acute-phase responses. Serum amyloid A3 (SAA3) is elevated in lupus-prone mice and may participate in the immune link between liver inflammation and macrophage responses. Jieduquyuziyin Prescription (JP) is a traditional formula used clinically for SLE, but its chemical basis and SAA3-related immunomodulatory mechanisms remain incompletely defined. PURPOSE This study investigated the effects of JP on SLE-related inflammatory phenotypes, hepatocyte SAA3 expression, and macrophage MAPK14/p38-related M1 polarization responses, and examined the interaction between representative JP constituents and MAPK14. METHODS MRL/Lpr mice were used to evaluate the in vivo effects of JP. LC-MS and HPLC were used for chemical characterization. Network pharmacology, primary splenic macrophages, primary hepatocytes, and macrophage-naive CD4⁺ T cell co-culture systems were used to characterize JP-associated immune responses. Western blotting, flow cytometry, ELISA, and immunofluorescence were performed to assess p38 phosphorylation, macrophage polarization, cytokines, and SAA3. Molecular docking, SPR, molecular dynamics simulations, and ADP-Glo™ kinase assay were used to evaluate MAPK14 binding and kinase activity modulation by representative constituents. RESULTS JP treatment improved survival and renal-related indices in MRL/Lpr mice, accompanied by lower serum SAA3 levels, reduced splenic F4/80⁺ CD86⁺ macrophages, and decreased F4/80/iNOS signals. JP-medicated serum reduced SAA3-induced p38 phosphorylation, iNOS expression, and IL-6 and IL-1β release, while increasing Arg-1 expression and F4/80⁺ CD206⁺ cells. JP-medicated serum also reduced IL-6-induced SAA3 expression in hepatocytes. In co-culture, systems containing SAA3-treated macrophages showed increased CD4⁺ IL-17A⁺ cells and IL-17 levels, whereas JP treatment reduced these readouts. Hesperidin, glycyrrhizic acid, and paeoniflorin were detected in JP decoction and JP-medicated serum and generated measurable binding responses to MAPK14. The three-compound mixture and individual constituents reduced recombinant MAPK14 kinase activity, with stronger activity observed for the mixture. CONCLUSION JP treatment was associated with reduced hepatocyte SAA3 expression, attenuated macrophage MAPK14/p38-related M1 inflammatory responses, and decreased Th17-associated inflammatory indices. MAPK14 may serve as a mechanistically relevant molecular node engaged by representative JP constituents, providing experimental support for JP-mediated regulation of SLE-related inflammatory networks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serum Amyloid A ProteinLupus Erythematosus, SystemicMacrophagesDrugs, Chinese HerbalMitogen-Activated Protein Kinase 14AnimalsFemaleMiceMice, Inbred MRL lprHepatocytesp38 Mitogen-Activated Protein Kinases

Stichwörter der Autor:innen

Jieduquyuziyin prescriptionMacrophage polarizationMapk14Serum amyloid a3Systemic lupus erythematosus

Substanzen

Serum Amyloid A ProteinDrugs, Chinese HerbalMitogen-Activated Protein Kinase 14Saa3 protein, mousep38 Mitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Key Laboratory of Chinese Medicine Rheumatology of Zhejiang Province, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
  • Department of Anesthesiology, Zhejiang Cancer Hospital, Laboratory of Anesthesia and Perioperative Medicine, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
  • Key Laboratory of Chinese Medicine Rheumatology of Zhejiang Province, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China; Jinhua Academy, Zhejiang Chinese Medical University,…
  • Jinhua Academy, Zhejiang Chinese Medical University, Jinhua, China.
  • Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
  • School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.

Förderung

  • Zhejiang Province Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Lu, X., Huang, Y., Liu, M., Xu, L., Chen, X., Wei, Y., Zhou, Y., Jin, H., Lu, F., Tang, Y., & Wen, C. (2026). Jieduquyuziyin prescription ameliorates systemic lupus erythematosus by targeting MAPK14 to inhibit SAA3-induced macrophage M1 polarization. Phytomedicine, 160, 158659. https://doi.org/10.1016/j.phymed.2026.158659

Vancouver

Lu X, Huang Y, Liu M, Xu L, Chen X, Wei Y, et al. Jieduquyuziyin prescription ameliorates systemic lupus erythematosus by targeting MAPK14 to inhibit SAA3-induced macrophage M1 polarization. Phytomedicine. 2026;160:158659. doi:10.1016/j.phymed.2026.158659

BibTeX
@article{Lu2026,
  author = {Lu, Xinhui and Huang, Yan and Liu, Manchao and Xu, Li and Chen, Xi and Wei, Yinghui and Zhou, Yihan and Jin, Hang and Lu, Fengyu and Tang, Yujun and Wen, Chengping},
  title = {Jieduquyuziyin prescription ameliorates systemic lupus erythematosus by targeting MAPK14 to inhibit SAA3-induced macrophage M1 polarization},
  journal = {Phytomedicine},
  year = {2026},
  volume = {160},
  pages = {158659},
  doi = {10.1016/j.phymed.2026.158659}
}
Kostenlos starten →